347
On 6 November 2006, a new orphan medicinal product was registered into the community register of orphan medicinal products under the EU orphan designation number 411. The active ingredient is recombinant fusion protein consisting of the extracellular portion of CD95 fused to the Fc part of a human IgG1 molecule for prevention of Graft-versus-Host disease.